Glycoair Breezhaler Dosage/Direction for Use

General target population: The recommended dosage is the once-daily inhalation of the content of one 110/50 microgram capsule using the Breezhaler inhaler.
Special populations: Renal impairment: Indacaterol/glycopyrronium can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk. See also Precautions and Pharmacology under Actions.
Hepatic impairment: Indacaterol/glycopyrronium can be used at the recommended dose in patients with mild and moderate hepatic impairment. No data are available for subjects with severe hepatic impairment. See also Pharmacology under Actions.
Pediatric patients (below 18 years): Indacaterol/glycopyrronium should not be used in patients under 18 years of age.
Geriatric patients (75 years or above): Indacaterol/glycopyrronium can be used at the recommended dose in elderly patients 75 years of age and older.
Method of administration: Indacaterol/glycopyrronium capsules must be administered only by the oral inhalation route and only using the Breezhaler inhaler. Capsules must not be swallowed (see also Overdosage).
It should be administered at the same time of the day each day. If a dose is missed, it should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.
Capsules must always be stored in the blister to protect from moisture, and only removed IMMEDIATELY BEFORE USE (see also Storage).
When prescribing indacaterol/glycopyrronium patients should be instructed on correct use of the inhaler. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it.